ALK抑制剂相关心血管毒性:VigiBase不成比例分析
基于VigiBase数据库1968年至2021年数据,分析五种ALK抑制剂与21种心血管不良事件的关联。结果显示仅心包炎在全部五种药物中均检出信号,而QT延长/尖端扭转型室速、高血压和心衰的信号因药物而异。各药心包炎起病时间从52.5天至166.5天不等。
要点
- 心包炎是五种ALK抑制剂共有的心血管毒性信号
- QT延长/尖端扭转型室速信号见于克唑替尼和色瑞替尼
- 高血压信号仅见于布格替尼,心衰信号见于阿来替尼、克唑替尼和劳拉替尼
核心结论
- 五种ALK抑制剂均检出心包炎信号,但其他心血管毒性信号因药物不同而异。
- 了解各ALK抑制剂心血管毒性谱的差异有助于药物切换时的安全用药。
研究设计与样本
- 基于VigiBase数据库1968年至2021年12月的个体安全报告,采用报告比值比(ROR)进行不成比例分析。
- 共纳入27994584份报告,其中19911份涉及ALK抑制剂治疗。
- 分析五种ALK抑制剂(克唑替尼、色瑞替尼、阿来替尼、布格替尼、劳拉替尼)与21种心血管不良事件的关联。
主要发现
- 心包炎信号在全部五种ALK抑制剂中均检出:克唑替尼ROR 4.7(95%CI 3.63-6.15),色瑞替尼ROR 12.9(95%CI 9.37-17.79),阿来替尼ROR 4.8(95%CI 3.15-7.42),布格替尼ROR 3.5(95%CI 1.33-9.46),劳拉替尼ROR 6.4(95%CI 3.60-11.22)。
- QT延长/尖端扭转型室速信号见于克唑替尼(ROR 5.0,95%CI 3.72-6.77)和色瑞替尼(ROR 4.2,95%CI 2.17-8.05)。
- 高血压信号仅见于布格替尼(ROR 3.9,95%CI 2.88-5.20)。
- 心衰信号见于阿来替尼(ROR 2.2,95%CI 1.60-2.90)、克唑替尼(ROR 2.1,95%CI 1.72-2.48)和劳拉替尼(ROR 2.0,95%CI 1.27-3.23)。
- 心包炎起病时间从阿来替尼的52.5天至克唑替尼的166.5天不等。
临床怎么用
- 临床使用ALK抑制剂时应监测心包炎相关症状,尤其关注各药特有的心血管毒性。
- 在ALK抑制剂之间切换时,应评估既往心血管毒性史及新药的心血管毒性谱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Recently, cases of cardiovascular toxicities, such as pericarditis, caused by anaplastic lymphoma kinase (ALK) inhibitors have been reported; however, whether these adverse events are common among all ALK inhibitors remains unclear. AIMS: This study aimed to clarify the cardiovascular toxicity profile of ALK inhibitors using an adverse event spontaneous report database. METHODS: We analyzed data from VigiBase, the WHO global database of individual safety reports, from its inception in 1968 to December 2021. We calculated the reporting odds ratio to evaluate the association between ALK inhibitors (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib) and 21 cardiovascular adverse events. Time to onset of pericarditis from ALK inhibitor administration was analyzed. RESULTS: Of the 27,994,584 reports, 19,911 involved treatment with ALK inhibitors. Among the 21 cardiovascular toxicities, only pericarditis signals were detected with all five ALK inhibitors (crizotinib [reporting odds ratios (ROR), 4.7; 95% CI 3.63-6.15], ceritinib [ROR, 12.9; 95% CI 9.37-17.79], alectinib [ROR, 4.8; 95% CI 3.15-7.42], brigatinib [ROR, 3.5; 95% CI 1.33-9.46], and lorlatinib [ROR, 6.4; 95% CI 3.60-11.22]). For torsade de pointes/QT prolongation, signals were detected with crizotinib (ROR, 5.0; 95% CI 3.72-6.77) and ceritinib (ROR, 4.2; 95% CI 2.17-8.05), whereas for hypertension, they were identified only with brigatinib (ROR, 3.9; 95% CI 2.88-5.20), and for heart failure, they were detected with alectinib (ROR, 2.2; 95% CI 1.60-2.90), crizotinib (ROR, 2.1; 95% CI 1.72-2.48), and lorlatinib (ROR, 2.0; 95% CI 1.27-3.23). Regarding time-to-onset analysis from drug administration to adverse event reporting, for pericarditis, it ranged from 52.5 days for alectinib to 166.5 days for crizotinib. CONCLUSIONS: Systematic evaluation of ALK inhibitor-associated adverse events revealed differences in the cardiotoxicity profiles among ALK inhibitors. Understanding the differences in the cardiovascular toxicity profile of each ALK inhibitor will contribute to safe drug therapy when switching between ALK inhibitors.
引用
- Niimura T, Miyata K, Hamano H, et al. Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase). Drug Saf. 2023. PMID: 37106270. doi:10.1007/s40264-023-01300-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。